Firebrick Pharma Limited (FRE.AX)

AUD 0.05

(1.89%)

Market Cap (In AUD)

11.34 Million

Revenue (In AUD)

14.52 Thousand

Net Income (In AUD)

-1.17 Million

Avg. Volume

105.83 Thousand

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.045-0.11
PE
-
EPS
-
Beta Value
1.606
ISIN
AU0000197352
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Dr. Peter Laurence Molloy BSc, FAICD, MBA
Employee Count
-
Website
https://www.firebrickpharma.com
Ipo Date
2022-01-27
Details
Firebrick Pharma Limited engages in the development and commercialization of nasal spray treatment for the common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.